Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

The One-Year Outcome of LuX-Valve Plus TRAVEL II Study was Officially Released at TCT 2024

WASHINGTON, Oct. 31, 2024 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR breakthroughs, has just released the 1-year outcome of LuX-Valve P...

2024-10-31 21:00 964

Ping An Health Achieves WONCA International Quality Dual Certifications Defining New Standards in Internet Healthcare Services

HONG KONG and SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited ("Ping An Good Doctor", "Ping An Health", or "the Company", Stock Code: 1833.HK) received the Digital Health Certification (DHC) and the Continuous Professional Development (CPD) certifications...

2024-10-31 20:14 1337

Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology

* Traditional methods for evaluating therapeutic efficacy and cardiotoxicity often lead to high failure rates during clinical trials, resulting in significant development costs * Human-specific diseases cannot be accurately modeled by animals, leading to limited medical options or advancemen...

2024-10-31 20:00 1025

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

ROCKVILLE, Md., Oct. 31, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the ...

2024-10-31 19:00 1485

Cancer trial: retraining immune cells offers new hope for patients in personalized medicine breakthrough

BOSTON, Oct. 31, 2024 /PRNewswire/ -- In a remarkable development for cancer research, patients with advanced-stage cancer have benefited from SUPLEXA, a personalized treatment that trains the patient's own immune cells to fight cancer. "Cancer often gains the upper hand by suppressing the imm...

2024-10-31 18:00 1119

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

* Celltrion USA has expanded access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous (SC) infliximab, to a significant share of the U.S. market * The availability of ZYMFENTRA will support greater patient access and choice while helping to drive greater affordabil...

2024-10-31 14:31 1011

Kelun-Biotech's TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC

CHENGDU, China, Oct. 31, 2024 /PRNewswire/ -- The new drug application (NDA) (the "Application") based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan (sac-TMT, formerly SKB264/MK-2870) developed by Sichuan Kelun-Biotech Biopharmaceutical Co., L...

2024-10-31 12:02 1448

MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

SHENZHEN, China, Oct. 30, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI") , a company committed to building core tools and technologies that drive innovation in life science, is thrilled to announce that its DNBSEQ-T20x2 Genetic Sequencer* has been recognized as a Specia...

2024-10-31 10:51 1332

MGI's DNBSEQ-T20 x2 Selected As A Special Mention In TIME Best Inventions 2024

Abionic's CAPSULE PSP Receives FDA Approval for Early Detection of Sepsis; Fapon Introduces Exclusive PSP Solution in China via Licensing Collaboration

DONGGUAN, China, Oct. 30, 2024 /PRNewswire/ -- Fapon, a global leading life sciences company, is thrilled to announce its PSP CLIA reagent solution which demonstrates promising outcomes in extensive clinical validation studies targeting Chinese population. Leveraging its strategic partnership ...

2024-10-31 10:26 1289

Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined with Ligufalimab (CD47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (HNSCC), Compared to Pembrolizumab

HONG KONG, Oct. 30, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the enrollment of the first patient in its randomized, controlled, multicenter Phase III clinical study (AK117-302) for head and neck squamous cell carcinoma. This trial evaluates the innovative PD-1/VEGF bi...

2024-10-31 08:46 1936

Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China

* Neurophet enters into a strategic agreement with LADO to distribute Neurophet SCALE PET * Improves the efficiency of market entry with expertise of medical device go-to-market process inChina through the establishment of joint venture SEOUL, South Korea, Oct. 30, 2024 /PRNewswire/ -- Neurop...

2024-10-30 21:00 1439

Neurophet partners with Beijing LADO Technology… Intends to establish Joint Venture in China

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) onSaturday, November 9, 2024 ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the develop...

2024-10-30 19:00 991

World Stroke Congress | TASTE-2 significantly reduces stroke disability

NANJING, China, Oct. 30, 2024 /PRNewswire/ -- Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) has been published at the 16th World Stroke...

2024-10-30 15:36 1232

World Stroke Congress | TASTE-2 significantly reduces stroke disability

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

RAMAT GAN, Israel, Oct. 30, 2024 /PRNewswire/ -- Pulsenmore (TASE: PULS), a pioneering provider of home-based ultrasound technology, has announced the renewal and expansion of its strategic partnership with Clalit Health Services, Israel's largest HMO. Over the next five years, Pulsenmore will sup...

2024-10-30 14:00 1001

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000 Home Ultrasound Devices for Remote Prenatal Care

Fosun Pharma Announces 2024Q3 Financial Results

Revenue Exceed RMB30.9 Billion with R&D Expenditure RMB3.9 Billion Continuing to Consolidate its Dominant Position In The fields of Breast Cancer and Lung Cancer SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- On October 29, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group";...

2024-10-30 10:41 1613

WuXi AppTec Named Global CRDMO Company of the Year by Frost & Sullivan for the Eighth Consecutive Year

SHANGHAI, Oct. 29, 2024 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, has been awarded the 2024 Global CRDMO Company of the Year Award by Frost & Sullivan, a gr...

2024-10-30 08:00 1174

Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting

* Pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) previously demonstrated superior efficacy of subcutaneous (SC) infliximab over placebo for maintenance therapy in patients with Crohn's disease (CD) and ulcerative colitis (UC)[1], [2] * ZYMFENTRA® is the first and only FDA-approved subcut...

2024-10-30 03:25 1223

DeepQure Presents Clinical Results of Laparoscopic RDN at TCT 2024, Demonstrating Cutting-edge Technology and Innovation

SEOUL, South Korea, Oct. 29, 2024 /PRNewswire/ -- DeepQure, a global pioneer in resistant hypertension treatment, has unveiled clinical results of its laparoscopic renal denervation (RDN) medical device "HyperQure". Designed to treat resistant hypertension,HyperQure uses a laparoscopic approach t...

2024-10-29 21:00 1447

Complete Genomics integrates NVIDIA Parabricks to offer researchers faster, more cost-effective and accurate genomic sequencing analysis

Complete Genomics DNBSEQ data and NVIDIA Parabricks yield deeper insights into genetic variants with deep learning SAN JOSE, Calif., Oct. 29, 2024 /PRNewswire/ -- Complete Genomics today announced an integration of its next-generation sequencing (NGS) DNBSEQ platforms* with NVIDIA Parabricks sof...

2024-10-29 21:00 1029

Qilian International Holding Group Limited Announces Name Change to BGM Group Ltd.

CHENGDU, China, Oct. 29, 2024 /PRNewswire/ -- Qilian International Holding Group Ltd. ("Qilian" or the "Company") (NASDAQ: BGM) is pleased to announce that effective onOctober 30, 2024, the Company will change its name to "BGM Group Ltd." In connection with the name change, the trading symbol of ...

2024-10-29 20:00 1819

1 2 3 456 7 8 ... 214

Week's Top Stories

Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies

[Picked up by 283 media titles]

2024-11-20 09:00